Status:
COMPLETED
CDP323 Biomarker Study
Lead Sponsor:
UCB Pharma
Collaborating Sponsors:
Biogen
Conditions:
Relapsing Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.
Eligibility Criteria
Inclusion
- Female and male subjects aged 18-65 years
- Relapsing form of MS with at least one clinical relapse in the 24 months before screening;
- Screening EDSS score of 0-6.5;
- Must be fully immunocompetent
- Female subjects of childbearing potential must agree to practice contraception methods
Exclusion
- Any conditions that could interfere with the contrast-enhanced MRI;
- Any clinically significant disease state or findings other than MS;
- Any clinically significant deviation from the pre-defined ranges for laboratory tests;
- Concomitant treatment with MS disease modifying drugs
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00726648
Start Date
July 1 2008
End Date
March 1 2009
Last Update
September 12 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tooting, London, United Kingdom
2
Croydon, Surrey, United Kingdom